XML 50 R39.htm IDEA: XBRL DOCUMENT
v3.25.3

REVENUE AND DEFERRED REVENUE (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
REVENUE AND DEFERRED REVENUE |
Schedule of percentages of deferred revenue by year | As of September 30, 2025, the Company expects to recognize approximately the following percentages of deferred revenue by year: ​
​ | ​ | ​ | ​
​ |  | Revenue |
Year: | ​ | Recognition |
Remainder of 2025 | ​ | 46 | %
2026 |  | 54 | %
Total |  | 100 | %
Schedule of revenue generated in geographic regions for years indicated | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Revenues by Geography |
​ | ​ | Three Months Ended September 30, |
​ | ​ | 2025 | ​ | 2024 |
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | ​ | % of |
​ | ​ | Amount | ​ | Revenues | ​ | Amount | ​ | Revenues |
​ | ​ | (in thousands, except percentages) | ​
U.S. |  | $ | 36,248 |  | 97 | % | $ | 17,922 |  | 97 | %
International | ​ |  | 1,049 |  | 3 | % |  | 608 |  | 3 | %
Total revenues | ​ | $ | 37,297 |  | 100 | % | $ | 18,530 |  | 100 | %
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Revenues by Geography |  | ​
​ | ​ | Nine Months Ended September 30, |  | ​
​ | ​ | 2025 | ​ | 2024 |  | ​
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | ​ | % of |  | ​
​ | ​ | Amount | ​ | Revenues | ​ | Amount | ​ | Revenues |  | ​
​ | ​ | (in thousands, except percentages) | ​ | ​
U.S. |  | $ | 105,387 |  | 98 | % | $ | 50,845 |  | 97 | % | ​
International | ​ |  | 1,993 |  | 2 | % |  | 1,552 |  | 3 | % | ​
Total revenues | ​ | $ | 107,380 |  | 100 | % | $ | 52,397 |  | 100 | % | ​
U.S. |
REVENUE AND DEFERRED REVENUE |
Schedule of revenue generated in product category for years indicated | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | U.S. Revenues by Product Category |
​ | ​ | Three Months Ended September 30, |
​ | ​ | 2025 | ​ | 2024 |
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | % of |
​ |  | Amount |  | Revenues |  | Amount |  | Revenues |
​ |  | (in thousands, except percentages) | ​
NeuroStar Advanced Therapy System | ​ | $ | 3,508 | ​ | 10 | % | $ | 4,108 | ​ | 23 | %
Treatment sessions | ​ |  | 10,543 |  | 29 | % |  | 13,326 |  | 74 | %
Clinic revenue | ​ | ​ | 21,808 | ​ | 60 | % | ​ | — | ​ | — | %
Other | ​ |  | 389 |  | 1 | % |  | 488 |  | 3 | %
Total U.S. revenues | ​ | $ | 36,248 |  | 100 | % | $ | 17,922 |  | 100 | %
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | U.S. Revenues by Product Category |
​ | ​ | Nine Months Ended September 30, |
​ | ​ | 2025 | ​ | 2024 |
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | % of |
​ |  | Amount |  | Revenues |  | Amount |  | Revenues |
​ |  | (in thousands, except percentages) | ​
NeuroStar Advanced Therapy System | ​ | $ | 9,838 | ​ | 9 | % | $ | 11,418 | ​ | 22 | %
Treatment sessions | ​ |  | 30,928 |  | 30 | % |  | 37,974 |  | 75 | %
Clinic revenue | ​ | ​ | 63,491 | ​ | 60 | % | ​ | — | ​ | — | %
Other | ​ |  | 1,130 |  | 1 | % |  | 1,453 |  | 3 | %
Total U.S. revenues | ​ | $ | 105,387 |  | 100 | % | $ | 50,845 |  | 100 | %
International |
REVENUE AND DEFERRED REVENUE |
Schedule of revenue generated in product category for years indicated | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | International Revenues by Product Category |
​ | ​ | Three Months Ended September 30, |
​ | ​ | 2025 | ​ | 2024 |
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | ​ | % of |
​ |  | Amount |  | Revenues |  | Amount |  | Revenues |
​ |  | (in thousands, except percentages) | ​
NeuroStar Advanced Therapy System | ​ | $ | 448 |  | 43 | % | $ | 244 |  | 40 | %
Treatment sessions | ​ |  | 214 |  | 20 | % |  | 90 |  | 15 | %
Other | ​ |  | 387 |  | 37 | % |  | 274 |  | 45 | %
Total international revenues | ​ | $ | 1,049 |  | 100 | % | $ | 608 |  | 100 | %
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | International Revenues by Product Category |
​ | ​ | Nine Months Ended September 30, |
​ | ​ | 2025 | ​ | 2024 |
​ | ​ | ​ | ​ | ​ | % of | ​ | ​ | ​ | ​ | % of |
​ |  | Amount |  | Revenues |  | Amount |  | Revenues |
​ |  | (in thousands, except percentages) | ​
NeuroStar Advanced Therapy System | ​ | $ | 774 |  | 39 | % | $ | 502 |  | 32 | %
Treatment sessions | ​ |  | 644 |  | 32 | % |  | 400 |  | 26 | %
Other | ​ |  | 575 |  | 29 | % |  | 650 |  | 42 | %
Total international revenues | ​ | $ | 1,993 |  | 100 | % | $ | 1,552 |  | 100 | %
​

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |